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Abstract: Purpose: The pathophysiology of cervical dystonia (CD) is thought to be related to changes
in dopamine and serotonin levels in the brain. We performed a double-blind trial with escitalopram
(selective serotonin reuptake inhibitor; SSRI) in patients with CD. Here, we report on changes in
dopamine D2/3 receptor (D2/3R), dopamine transporter (DAT) and serotonin transporter (SERT)
binding potential (BPND) after a six-week treatment course with escitalopram or placebo. Methods:
CD patients had [123I]FP-CIT SPECT (I-123 fluoropropyl carbomethoxy-3 beta-(4-iodophenyltropane)
single-photon emission computed tomography) scans, to quantify extrastriatal SERT and striatal
DAT, and [123I]IBZM SPECT (I-123 iodobenzamide SPECT) scans to quantify striatal D2/3R BPND
before and after six weeks of treatment with either escitalopram or placebo. Treatment effect was
evaluated with the Clinical Global Impression scale for dystonia, jerks and psychiatric symptoms,
both by physicians and patients. Results: In both patients treated with escitalopram and placebo
there were no significant differences after treatment in SERT, DAT or D2/3R BPND. Comparing scans
after treatment with escitalopram (n = 8) to placebo (n = 8) showed a trend (p = 0.13) towards lower
extrastriatal SERT BPND in the SSRI group (median SERT occupancy of 64.6%). After treatment
with escitalopram, patients who reported a positive effect on dystonia or psychiatric symptoms
had significantly higher SERT occupancy compared to patients who did not experience an effect.
Conclusion: Higher extrastriatal SERT occupancy after treatment with escitalopram is associated with
a trend towards a positive subjective effect on dystonia and psychiatric symptoms in CD patients.
Keywords: cervical dystonia; single-photon emission computed tomography (SPECT);
dopamine serotonin; escitalopram
1. Introduction
Cervical dystonia (CD) is the most common form of adult-onset, isolated, focal dystonia [1].
Besides dystonia of the neck muscles, patients often suffer from a variety of other symptoms, such as
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jerks or head tremor (around 50% of patients) [2] and psychiatric symptoms, mainly depression and
anxiety (lifetime prevalence between 40–90%) [3,4].
The pathophysiology of CD and other forms of dystonia is not fully understood, but alterations in
neurotransmitters such as dopamine and serotonin are hypothesized to play an important role [5,6].
In line with this hypothesis, in two recent single-photon emission computed tomography (SPECT)
studies in CD, we have shown that abnormalities in central dopaminergic and serotonergic systems
are mainly related to depressive symptoms [7,8].
Treatment with selective serotonin re-uptake inhibitors (SSRIs) is an effective pharmacological
intervention for major depression [9]. After short-term treatment with SSRIs (4–6 weeks), serotonin
transporter (SERT) binding in midbrain, thalamus and striatum is significantly reduced (40–70%) in
depressed patients as well as healthy controls, representing occupancy of the SERT by the SSRI [10–12].
Treatment of major depression with a therapeutic dose of different SSRIs led to midbrain SERT occupancy
of around 80%, if measured shortly after ingestion of the last SSRI dosage [13–15]. Increasing the SSRI
dose leads to higher plasma levels but SERT occupancy does not further increase (ceiling effect). This is
in line with the fact that increasing the dose of an SSRI does not increase treatment efficacy [16],
but may lead to more side effects, likely (partly) caused by an effect of SSRIs on other neurotransmitter
systems, such as the dopamine system. It was found that the striatal DAT binding is significantly
increased by approximately 20% during a successful six-week treatment course with an SSRI, although
this effect is smaller in older patients [11].
In dystonia, the role of the serotonin system is far less clear than in major depression. However,
serotonergic abnormalities are likely to play a role in the pathophysiology of CD (for a recent review
see Smit and co-workers) [6]. Recently, we conducted a crossover trial with the SSRI escitalopram,
to evaluate the efficacy in CD with jerks/tremor. In this particular study, we did not find an add-on
SSRI treatment effect to botulinum neurotoxin (BoNT) comparing a six-week treatment course
with escitalopram or placebo [17]. To examine SERT occupancy, and the relationship between
SERT occupancy and clinical effect, as well as to evaluate the effect of SSRI treatment in CD on
the dopaminergic system, we studied the effect on both the dopamine and serotonin system in each
subject, before and after treatment with serial SPECT scans. In the current article, we report the effects
on DAT, D2/3 receptors (D2/3R) and SERT BPND, as measured with SPECT, in relation to the clinical
effect. We hypothesized that in CD patients treated with placebo tracer binding to DAT, D2/3R and
SERT would remain unchanged. In CD patients treated with escitalopram, we hypothesized that SERT
binding would be significantly reduced (representing occupancy, expected around 80%) and D2/3R
and DAT binding would be increased. Furthermore, we investigated whether SERT occupancy and
change in D2/3R and DAT binding were related to clinical outcomes.
2. Material and Methods
2.1. Subjects
Inclusion and exclusion criteria have been published previously [7]. In short, patients were
eligible to participate if they were between 35 and 80 years old and had idiopathic CD that had been
clinically stable for at least one year on the Tsui scale for dystonia severity with three-times-monthly
BoNT injections. Exclusion criteria were other neurological conditions at inclusion or in the past,
treatment with deep brain stimulation for dystonia, use of medication with a known dopaminergic or
serotonergic effect during the study or in the 20 weeks preceding the baseline scans [18], and pregnancy
or lactation. Neurological examination was normal except for dystonia, myoclonus and tremor in all
patients. BoNT injections were administered at the first day of the medication trial or a maximum of
7 days prior/after starting the medication. Thus, baseline scans were acquired within a week of BoNT
injections and follow-up scans were made between 5–7 weeks after BoNT injections.
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2.2. Ethical Compliance
This study was approved by the Ethical Committee of the AMC (MEC10/036; approved date
31 May 2010), and informed consent was obtained from all patients. We confirm that we have read
the Journal’s position on issues involved in ethical publication and affirm that this work is consistent
with those guidelines.
2.3. Experimental Design and Treatment
Patients in the present imaging substudy participated in a larger randomized, double-blind,
placebo-controlled, crossover trial, containing a total of 53 patients. For the details regarding
randomization and treatment assignment, we refer to our previously published article [17]. In short,
patients were randomly assigned to first receive one of two treatment options for the duration of six
weeks: escitalopram 10 mg once daily, or placebo. Randomization per block of 4 subjects was performed
and the treatment was blinded for both the patients and the investigator. The patients we report
on in the current substudy are a subgroup that had baseline SPECT scans and neurological and
psychiatric examination before start of the medication trial [7,8]. Medication was started immediately
after all three baseline scans were performed (see Section 2.5). Both baseline scans ([123I]-FP-CIT
(I-123 fluoropropyl carbomethoxy-3 beta-(4-iodophenyltropane)) and [123I]IBZM (I-123 iodobenzamide)
SPECT; see Section 2.5) were acquired within 3 to 7 days of each other. The repeat SPECT scans (also
made within 3 to 7 days of each other), as well as the neurological and psychiatric examinations were
performed after a six-week treatment course with escitalopram or placebo. At the same time blood for
analysis of plasma levels of escitalopram was withdrawn and stored at −20 ◦C until analysis. Samples
were analysed in batches of 10–20 samples at a time using a validated LC-MS/MS method (liquid
chromatography–mass spectrometry/mass spectrometry; range of detection 5–500 µg/L) [19]. The last
dosage of medication had been less than 24 h before the scan for both scans. After a washout period of
2–6 weeks, interventions were switched. The halftime of escitalopram is 30 h, so a minimum period of
2 weeks was sufficient to washout escitalopram completely. Because of radiation burden, scans were
not repeated after the second treatment round.
2.4. Scoring Neurological and Psychiatric Symptoms
Patients were systematically neurologically and psychiatrically examined, as published
previously [7]. This examination was performed on the day the first SPECT scan was made and
consisted of video recordings, a psychiatric interview and questionnaires. The detailed results of
the effect of escitalopram and placebo on these examinations have been reported previously [17].
Considering the small sample size of the current study, we only incorporated the Clinical Global
Impression Scale (CGI) [20], which is a seven-point scale of disease severity were lower scores indicate
less symptoms. This question was answered for jerks, psychiatric symptoms and dystonia separately,
both objectively by the physician and subjectively by the patient. We used the CGI to classify patients
as responders (defined as a decrease of ≥1 point on CGI compared to baseline) or nonresponders (CGI
same or higher compared to baseline). This was done separately for the three symptoms, and separately
by patient and physician.
2.5. SPECT Imaging
All patients received 300 mg potassium iodide to block thyroid uptake of free radioactive iodide
before administration of the tracer. Both striatal DAT and diencephalon/midbrain SERT were imaged
using [123I]FP-CIT SPECT, a technique that has been validated before [21,22]. Subjects received a mean
dose of 100 MBq of [123I]FP-CIT intravenously (produced according to GMP criteria by GE Healthcare)
as a bolus [23]. Scans were performed 2 h after bolus injection to visualize and quantify the SERT binding
in diencephalon/midbrain and 3 h after bolus injection to visualize and quantify the DAT binding in
the striatum [24]. To visualize striatal D2/3R binding, subjects received a 56 MBq bolus of [123I]IBZM
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intravenously (produced according to GMP criteria by GE Healthcare) followed by continuous infusion
of 14 MBq/h of [123I]IBZM until the end of the scan to achieve unchanging regional brain activity
levels [25,26]. Acquisition of the images was started 2 h after the bolus injection [25,27]. All SPECT
studies were performed on a 12-detector single-slice brain-dedicated scanner (Neurofocus 810, which is
an upgrade of the Strichmann Medical Equipment) with a full-width at half-maximum resolution of
approximately 6.5 mm, throughout the 20-cm field-of-view. After positioning of the subjects with
the head parallel to the orbitomeatal line, axial slices parallel and upward from the orbitomeatal
line to the vertex were acquired in 5 mm steps. An average of 15 slices was acquired in a 64 × 64
matrix. Scanning time was 3.5 min per slice for [123I]FP-CIT and 5 min per slice for [123I]IBZM SPECT
studies. The energy window was set at 140–178 keV. Images were reconstructed in 3-D mode and
analysed blindly by one observer (EZ). To quantify extrastiatal SERT, fixed regions of interest (ROIs)
for the diencephalon and midbrain combined were positioned as earlier described [22]. To quantify
striatal DAT, fixed ROIs for striatum were positioned as previously described [28]. The cerebellum
was used as reference region for diencephalon/midbrain SERT binding as well as for striatal DAT
binding [22]. For the [123I]IBZM images, fixed ROIs for the striatum were positioned on the occipital
cortex on the same slices that were used as reference regions [29]. In all cases, specific to nonspecific
binding ratios were calculated as [(activity in ROI–activity in reference region)/activity in reference
region], representing the binding potential (BPND) [30]. BPND is a combined measure of the density
of available neuroreceptors/transporters and tracer affinity to the neuroreceptor/transporter. SERT
occupancy was calculated as (BPND at baseline-BPND after escitalopram)/BPND at baseline * 100.
2.6. Statistical Analysis
The Mann–Whitney U test was used to calculate differences in BPND between different groups at
baseline and Wilcoxon matched pairs signed rank-sum t-test was used to calculate differences in BPND
before and after treatment. Spearman’s correlation was used to examine a possible correlation between
escitalopram plasma levels and SERT occupancy. Analyses were carried out using SPSS (statistical
package for the social sciences; version 24 and differences were considered significant at p < 0.05.
3. Results
In total, before- and after-treatment SPECT scans were acquired in 10 patients treated with
escitalopram and in 8 patients treated with placebo. Despite indicating that they took all medication,
two patients in the escitalopram group had nonmeasurable plasma levels and were excluded from
the remainder of the analyses. Analyses were performed using the remaining 8 patients. As expected,
none of the patients in the placebo group had measurable plasma levels of escitalopram. Baseline
characteristics are depicted in Table 1. At baseline, 11/16 patients (69%; 5 in the placebo group and
6 in the escitalopram group) fulfilled the criteria for a psychiatric disorder. In total 8/16 patients
fulfilled the criteria for an anxiety disorder (50%; 3 in the placebo group and 5 in the escitalopram
group) and 3/16 patients fulfilled the criteria for a mood disorder (19%; 1 in the placebo group and 2 in
the escitalopram group). There were no significant differences in baseline extrastriatal SERT, striatal
DAT or striatal D2/3R BPND between patients randomized to be treated with escitalopram first and
patients randomized to be treated with placebo first.
Table 1. Baseline Characteristics.
Variables Escitalopram (n = 8) Placebo (n = 8) p-Value
Age, mean (SD) 56.4 (9.1) 56.8 (10.3) 0.94
Male, n (%) 4 (50%) 6 (75%) 0.61
n = number, SD = Standard deviation.
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3.1. Difference between Baseline Scans and Scans after Treatment
There was no significant difference in extrastriatal SERT, striatal DAT or striatal D2/3R BPND
between baseline and treatment with placebo. In patients treated with escitalopram, SERT BPND and
DAT BPND were lower and D2/3R BPND was higher after treatment compared to baseline. However,
the variability of the measurements was high, and results failed to reach statistical significance (Table 2).
Table 2. Comparison of SPECT Measures (BPND) between Pre- and Post-Treatment.
Baseline After Treatment p-Value
Escitalopram (n = 8)
SERT 0.18 (0.12−0.31) 0.05 ((−0.02)−0.28) 0.26
DAT 3.31 (2.47−4.10) 2.90 (2.65−3.97) 0.40
D2/3R 0.71 (0.60−0.92) 0.89 (0.50−0.92) 0.60
Placebo (n = 8)
SERT 0.28 (0.16−0.38) 0.20 (0.08−0.39) 0.40
DAT 3.54 (3.40−3.62) 3.71 (3.34−4.56) 0.61
D2/3R 0.92 (0.62−1.13) 0.88 (0.84−1.03) 0.73
Extrastriatal SERT and striatal DAT were measured with [123I]FP-CIT SPECT, and striatal D2/3R with [123I]IBZM
SPECT. Data are depicted as median (interquartile range).
3.2. Differences between SSRI and Placebo
There was a trend towards a lower median diencephalon/midbrain SERT BPND in patients treated
with escitalopram (0.05 (IQR(interquartile range)−0.02−0.28) compared to patients treated with placebo
(0.20 (IQR 0.08−0.39); p = 0.13 (see Figure 1)). Median SERT occupancy was 64.6% in the escitalopram
group (IQR 1.2−91.9%). There was no significant difference in DAT BPND (p = 0.40) or D2/3R BPND
(p = 0.46) between the treatment groups.
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Figure 1. Median SERT BPND and interquartile range after treatment with placebo and escitalopram.
After treatment with escitalopram, patients that indicated on the CGI that dystonia improved
(n = 6) had a trend towards lower extrastriatal SERT BPND on the post-treatment scan compared to
patients (n = 2) that indic ted that severity of dystonia was the same or wors (0.03 (IQR −0.04−0.10)
vs. 0.33 (IQR 0.29-NA); p = 0.07). The median occupancy of SERT was 71.6% in patients that
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indicated dystonia improved on the CGI. SERT was not occupied in patients that did not indicate
improvement (p = 0.14).
Patients (n = 5) that indicated on the CGI that their psychiatric symptoms (depressive symptoms
and anxiety) improved after treatment with escitalopram had significantly lower SERT BPND on
the post-treatment scan compared to patients (n = 3) that indicated that severity of psychiatric symptoms
was the same or worse (0.01 (IQR −0.04−0.05) vs. 0.29 (IQR 0.25-NA); p = 0.04). The median occupancy
of SERT by escitalopram was 76.5% in patients that indicated psychiatric symptoms improved,
and SERT was less occupied in patients that did not indicate improvement (median occupancy −9%;
p = 0.04).
In the escitalopram group, there was no significant difference in extrastriatal SERT BPND or
occupancy between patients who indicated they did or did not improve in terms of jerks. There was
no difference in DAT BPND and D2/3R BPND between escitalopram-treated patients who indicated
they improved on dystonia, jerks or psychiatric symptoms compared to patients who did not improve.
There was also no difference in SERT, DAT and D2/3R BPND between escitalopram-treated patients
who did and did not improve in terms of dystonia, jerks or psychiatric symptoms according to
the physicians.
Median plasma level of escitalopram was 21.0 µg/L (IQR 10.9−25.8). There was no correlation
between SERT occupancy and plasma levels of escitalopram (correlation coefficient 0.21, p = 0.61).
There was also no correlation between SERT BPND either pre- or post-treatment and plasma levels
of escitalopram.
In the placebo group, there were no differences in SERT, DAT and D2/3R BPND between patients
who did and did not improve in term of dystonia, jerks or psychiatric symptoms according to either
the patients or the physicians.
4. Discussion
In our study, we found no significant difference in SERT, DAT and D2/3R BPND before and after
treatment with either escitalopram or placebo. However, we did find a trend towards a difference in
SERT BPND after treatment with escitalopram compared to placebo. Furthermore, after treatment with
escitalopram, we found a significant higher SERT occupancy in patients who reported an improvement
of psychiatric symptoms compared to those who did not. A trend towards a significant higher SERT
occupancy was found in patients who reported an improvement of dystonia compared to those who
did not.
The trend towards a lower SERT BPND in the escitalopram group represents occupancy of SERT
of 65%. The lack of a statistically significant occupancy of SERT after a six-week treatment course
was likely due to a combination of factors. One factor was low baseline extrastriatal SERT BPND.
Low baseline SERT binding is in line with previous human [123I]FP-CIT SPECT studies [22,31,32], and
is related to the modest affinity of the radiotracer for the SERT [33]. The BPND levels did reduce to
around 0 after treatment (see Table 2), reflecting substantial SERT occupancy, but the absolute difference
in BPND was small. Another factor was that in our study the last tablet of escitalopram was taken the
day before the scans were made. In healthy subjects using 10 mg escitalopram once daily for 10 days,
SERT occupancy in the midbrain 6 and 54 h after ingestion of the last tablet showed a decrease from
82% after 6 h to 63% after 54 h [14]. It is likely that this effect also contributed to the relatively low
SERT occupancy we found. However, our present study was not designed to test whether [123I]FP-CIT
SPECT can be used to measure SERT occupancy by an SSRI, as this has been proven in several other
experimental studies [12,31], but to evaluate the relationship between SERT occupancy and clinical
effects. Nevertheless, in future studies focussing on SERT occupancy by an SSRI in dystonia, it might
be better to assess the occupancy shortly after (supervised) administration of the last tablet.
There was no significant relationship between SERT occupancy and plasma levels of escitalopram,
likely due to the ceiling effect where maximum SERT occupancy of around 80% is reached at relatively
low dosages of SSRIs [13,31].
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We believe that the difference in SERT BPND after citalopram presents predominantly occupancy
of the SERT by the SSRI escitalopram. Indeed, in a previous [123I]FP-CIT SPECT study in healthy
volunteers, we demonstrated that acute oral administration of the SSRI paroxetine can significantly
block extrastriatal [123I]FP-CIT binding.31 In the present study, however, the subjects were treated for
six weeks. Therefore, we cannot exclude that on top of the occupancy of the SERT by citalopram, also
compensatory molecular mechanism has occurred, e.g., downregulation of the SERT, which might
have slightly influenced the determination the SERT occupancy.
The most surprising, but interesting, finding of our study was that after escitalopram treatment
patients, with high SERT occupancy reported a better clinical effect on dystonia and psychiatric
symptoms compared to patients with low SERT occupancy. This effect was defined as a decrease of
≥1 point on self-reported CGI severity scores and there was no difference in an objective physician
CGI score of disease severity. Because of the small sample size, we did not incorporate scores from
depression or anxiety questionnaires, such as the Beck Depression Inventory or Beck Anxiety Inventory.
However, our finding indicates that in patients whereby most SERTs are blocked by escitalopram
experience a larger subjective treatment effect. Such a relationship between SERT occupancy and
treatment effect has not been demonstrated in patients with major depression [16]. However, in patients
with obsessive-compulsive disorder using sertraline, another SSRI, a positive relationship was detected
between pre-treatment/baseline SERT BPND measured with [123I]β-CIT SPECT in the thalamus and
hypothalamus and higher SERT occupancy, as well as better treatment response [34]. This is of interest
since sertraline is the SSRI with the highest affinity for the DAT, thus an effect of SERT occupancy on
treatment response can be debated. An alternative explanation for our finding of higher levels of SERT
occupancy in patients with a positive subjective response is that increased SERT occupancy led patients
to provide more positive answers. This was previously shown in patients with major depression
and severe pessimistic attitudes who had low extracellular serotonin levels. These levels could be
raised by the serotonin releaser d-fenfluramine, which led to more optimism in these patients [35].
A pessimistic attitude at baseline could have led to a high score on the CGI severity scale given by
the patients and a shift towards optimism would have made the patients give themselves a better score.
This might explain why there was a relationship between SERT occupancy and the positive subjective
scores of the patients, but a lack of such a relationship between SERT occupancy and the objective
physician scores.
In contrast with our hypothesis, no significant differences were found in striatal DAT BPND after
treatment with escitalopram. Although not significant, the median DAT BPND we found in this current
study was 14% lower after treatment with escitalopram compared to baseline. From studies in patients
with major depression, we know that SSRIs have an effect on the dopaminergic system, but the decrease
in DAT BPND is much smaller (around 20%) than the decrease in SERT BPND (40−70%). Furthermore,
the decrease in DAT BPND is smaller in older patients [11]. There are also indications that the decrease
in DAT BPND is related to the used reference region, at least when using nonselective tracers like
[123I]FP-CIT. When using the occipital cortex as reference tissue, a larger effect on DAT BPND was found
than when using the cerebellum, probably because of a higher concentration of SERTs in the occipital
cortex. Other factors that can explain why some studies found an effect of SSRIs on striatal DAT BPND
while others did not are intravenously given medication versus oral ingestion, chronic treatment with
SSRIs versus acute administration of a single dose, and perhaps the cohort under study (patients like
CD versus healthy controls may show a different neurotransmitter response).
We also did not find significant changes in D2/3R BPND after treatment with escitalopram.
In patients with major depression, overall no treatment effect on D2/3R BPND was found using
[123I]IBZM SPECT, but there were indications of a relationship between D2/3R BPND before and after
treatment with either the SSRI paroxetine or fluoxetine. Patients that responded well to SSRIs had lower
D2/3R BPND at baseline and D2/3R BPND increased after treatment [36]. We did not find a correlation
between D2/3R BPND and treatment response, neither for the objective scores of the physicians, nor for
the patients’ subjective scores.
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This study has some limitations. The most important limitation is the sample size. This is especially
important when measuring extrastriatal SERT BPND with [123I]FP-CIT SPECT of which it has been
established that the BPND is lower with a larger range compared to striatal DAT BPND (measured with
[123I]FP-CIT SPECT) or D2/3R BPND (measured with [123I]IBZM SPECT) [22,37]. A higher variability
makes it statistically more difficult to detect small differences. Furthermore, we used [123I]FP-CIT
to image both DAT and SERT BPND in the same patients. [123I]FP-CIT is a nonselective DAT/SERT
SPECT tracer that can reliably be used to measure SERT BPND in the diencephalon/midbrain but not
in other relevant brain regions like the striatum. In addition, we had to exclude two patients from
the escitalopram group because of nondetectable escitalopram plasma levels. This might indicate
they did not take medication; however, we cannot exclude that they were so-called fast metabolizers.
In a study where 8 healthy controls were treated with the SSRI paroxetine for 8 days, and all tablets
were ingested under supervision, one patient had nondetectable plasma levels of paroxetine and was
considered a fast metabolizer [38]. We could measure plasma levels of ≥5 µg/L and a plasma level of
5 µg/L has been proven to give an occupancy of >80% in the midbrain [13]. However, SERT occupancy
in these particularly two patients was in the negative range (BPND was even somewhat higher after
treatment compared to baseline; data not shown) making it unlikely that these patients had plasma
levels just below the detection range and making it more likely that they did not take study medication.
Lastly, here we only measure short-term effects with a treatment duration of six weeks. It is very
possible that with a longer treatment duration, neuroadaptive changes will occur and results will be
different. It would be interesting to investigate this in a larger study with a longer treatment duration,
for example a prospective cohort of patients with CD that are started on an SSRI to reduce psychiatric
symptoms and undergo SPECT scans before treatment and after 3–6 months of treatment.
In conclusion, we performed the first serial SPECT study in patients with CD treated with
escitalopram. We found a trend towards lower SERT BPND and consequently higher SERT occupancy
after treatment with escitalopram. Most interestingly, we found that within the group treated with
escitalopram, patients who reported subjective improvement in dystonia and/or psychiatric symptoms
had significantly lower SERT BPND and higher SERT occupancy than patients who did not improve.
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